Related references
Note: Only part of the references are listed.A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada-Clinical Trials Group Trial, MA.12)
V. H. C. Bramwell et al.
ANNALS OF ONCOLOGY (2010)
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
V. Ziller et al.
ANNALS OF ONCOLOGY (2009)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Good and poor adherence: optimal cut-point for adherence measures using administrative claims data
Sudeep Karve et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer
Gretchen Kimmick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
C. McCowan et al.
BRITISH JOURNAL OF CANCER (2008)
Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival
J. D. Wright et al.
BRITISH JOURNAL OF CANCER (2008)
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
Ann H. Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mortality impact of less-than-standard therapy in older breast cancer patients
Marianne Ulcickas Yood et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer
Xianglin L. Du et al.
CANCER (2007)
Early discontinuation of tamoxifen - A lesson for oncologists
Thomas I. Barron et al.
CANCER (2007)
Recurrences and second primary breast cancers in older women with initial early-stage disease
Ann M. Geiger et al.
CANCER (2007)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
Adherence to tamoxifen over the five-year course
Timothy L. Lash et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly
Alfred I. Neugut et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Validity of a prescription claims database to estimate medication adherence in older persons
R Grymonpre et al.
MEDICAL CARE (2006)
Racial disparities in treatment and survival among women with early-stage breast cancer
D Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug therapy - Adherence to medication
L Osterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer
RC Coombes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
PE Goss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy
JJ Griggs et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
AH Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Socioeconomic status and breast cancer incidence in California for different race/ethnic groups
K Yost et al.
CANCER CAUSES & CONTROL (2001)
Share Paper
